: Verve Therapeutics’ stock falls 40% as analysts question safety of cholesterol-cutting gene-editing treatment
Analysts raise concerns about comparative effectiveness of experimental cholesterol treatment.
More Stories
Fed’s Collins sees risk of economy slowing ‘beyond what is needed’
Boston Fed President Susan Collins said Tuesday that there are risks to the U.S. economy not only from sticky inflation,...
Boeing on the hook for $1 billion a month because of strike, as S&P frets anew
Boeing’s credit ratings at heightened risk of downgrade to junk as strike puts company’s recovery “at risk,” S&P says.
U.S. household energy bills won’t shock consumers this winter
U.S. consumers won’t see much of a change in the cost to heat their homes this winter compared to last...
Mark Cuban says Kamala Harris will tackle ‘criminal’ healthcare pricing schemes
Billionaire Mark Cuban has told Vice President Kamala Harris that one of her first priorities as president should be to...
‘It’s just almost impossible to do it all’: Here’s how much time and money the sandwich generation is spending on eldercare
Presidential candidate Kamala Harris says family caregivers need more help.
Microsoft’s stock heads for a ‘death cross’ — but there are bigger chart problems
A chart of Microsoft’s stock will soon flash a clearly visible bearish signal that’s been in the works for the...